A citation-based method for searching scientific literature

W Busse, J Corren, B Q Lanier, M McAlary, A Fowler-Taylor, G D Cioppa, A van As, N Gupta. J Allergy Clin Immunol 2001
Times Cited: 857







List of co-cited articles
935 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Mepolizumab treatment in patients with severe eosinophilic asthma.
Hector G Ortega, Mark C Liu, Ian D Pavord, Guy G Brusselle, J Mark FitzGerald, Alfredo Chetta, Marc Humbert, Lynn E Katz, Oliver N Keene, Steven W Yancey,[...]. N Engl J Med 2014
46

Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma.
Mario Castro, Jonathan Corren, Ian D Pavord, Jorge Maspero, Sally Wenzel, Klaus F Rabe, William W Busse, Linda Ford, Lawrence Sher, J Mark FitzGerald,[...]. N Engl J Med 2018
723
40

Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial.
Eugene R Bleecker, J Mark FitzGerald, Pascal Chanez, Alberto Papi, Steven F Weinstein, Peter Barker, Stephanie Sproule, Geoffrey Gilmartin, Magnus Aurivillius, Viktoria Werkström,[...]. Lancet 2016
647
38

Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
J Mark FitzGerald, Eugene R Bleecker, Parameswaran Nair, Stephanie Korn, Ken Ohta, Marek Lommatzsch, Gary T Ferguson, William W Busse, Peter Barker, Stephanie Sproule,[...]. Lancet 2016
666
36

Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials.
Mario Castro, James Zangrilli, Michael E Wechsler, Eric D Bateman, Guy G Brusselle, Philip Bardin, Kevin Murphy, Jorge F Maspero, Christopher O'Brien, Stephanie Korn. Lancet Respir Med 2015
640
36

The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
M Solèr, J Matz, R Townley, R Buhl, J O'Brien, H Fox, J Thirlwell, N Gupta, G Della Cioppa. Eur Respir J 2001
574
36

Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial.
Ian D Pavord, Stephanie Korn, Peter Howarth, Eugene R Bleecker, Roland Buhl, Oliver N Keene, Hector Ortega, Pascal Chanez. Lancet 2012
33

Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma.
Klaus F Rabe, Parameswaran Nair, Guy Brusselle, Jorge F Maspero, Mario Castro, Lawrence Sher, Hongjie Zhu, Jennifer D Hamilton, Brian N Swanson, Asif Khan,[...]. N Engl J Med 2018
469
32

Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma.
Elisabeth H Bel, Sally E Wenzel, Philip J Thompson, Charlene M Prazma, Oliver N Keene, Steven W Yancey, Hector G Ortega, Ian D Pavord. N Engl J Med 2014
893
32

Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma.
Parameswaran Nair, Sally Wenzel, Klaus F Rabe, Arnaud Bourdin, Njira L Lugogo, Piotr Kuna, Peter Barker, Stephanie Sproule, Sandhia Ponnarambil, Mitchell Goldman. N Engl J Med 2017
472
28

Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial.
Nicola A Hanania, Oral Alpan, Daniel L Hamilos, John J Condemi, Irmarie Reyes-Rivera, Jin Zhu, Karin E Rosen, Mark D Eisner, Dennis A Wong, William Busse. Ann Intern Med 2011
347
27

Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
M Humbert, R Beasley, J Ayres, R Slavin, J Hébert, J Bousquet, K-M Beeh, S Ramos, G W Canonica, S Hedgecock,[...]. Allergy 2005
712
24

International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma.
Kian Fan Chung, Sally E Wenzel, Jan L Brozek, Andrew Bush, Mario Castro, Peter J Sterk, Ian M Adcock, Eric D Bateman, Elisabeth H Bel, Eugene R Bleecker,[...]. Eur Respir J 2014
24

Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study.
Nicola A Hanania, Sally Wenzel, Karin Rosén, Hsin-Ju Hsieh, Sofia Mosesova, David F Choy, Preeti Lal, Joseph R Arron, Jeffrey M Harris, William Busse. Am J Respir Crit Care Med 2013
558
24

Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial.
Sally Wenzel, Mario Castro, Jonathan Corren, Jorge Maspero, Lin Wang, Bingzhi Zhang, Gianluca Pirozzi, E Rand Sutherland, Robert R Evans, Vijay N Joish,[...]. Lancet 2016
513
21

Omalizumab for asthma in adults and children.
Rebecca Normansell, Samantha Walker, Stephen J Milan, E Haydn Walters, Parameswaran Nair. Cochrane Database Syst Rev 2014
362
21

Reslizumab for Inadequately Controlled Asthma With Elevated Blood Eosinophil Levels: A Randomized Phase 3 Study.
Leif Bjermer, Catherine Lemiere, Jorge Maspero, Sivan Weiss, James Zangrilli, Matthew Germinaro. Chest 2016
242
19

Efficacy of mepolizumab add-on therapy on health-related quality of life and markers of asthma control in severe eosinophilic asthma (MUSCA): a randomised, double-blind, placebo-controlled, parallel-group, multicentre, phase 3b trial.
Geoffrey L Chupp, Eric S Bradford, Frank C Albers, Daniel J Bratton, Jie Wang-Jairaj, Linda M Nelsen, Jennifer L Trevor, Antoine Magnan, Anneke Ten Brinke. Lancet Respir Med 2017
288
18

Efficacy and safety of a recombinant anti-immunoglobulin E antibody (omalizumab) in severe allergic asthma.
S T Holgate, A G Chuchalin, J Hébert, J Lötvall, G B Persson, K F Chung, J Bousquet, H A Kerstjens, H Fox, J Thirlwell,[...]. Clin Exp Allergy 2004
373
18

Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.
Jonathan Corren, Steven Weinstein, Lindsay Janka, James Zangrilli, Margaret Garin. Chest 2016
223
17

Mepolizumab and exacerbations of refractory eosinophilic asthma.
Pranabashis Haldar, Christopher E Brightling, Beverley Hargadon, Sumit Gupta, William Monteiro, Ana Sousa, Richard P Marshall, Peter Bradding, Ruth H Green, Andrew J Wardlaw,[...]. N Engl J Med 2009
16

A randomized multicenter study evaluating Xolair persistence of response after long-term therapy.
Dennis Ledford, William Busse, Benjamin Trzaskoma, Theodore A Omachi, Karin Rosén, Bradley E Chipps, Allan T Luskin, Paul G Solari. J Allergy Clin Immunol 2017
98
15

Dupilumab in persistent asthma with elevated eosinophil levels.
Sally Wenzel, Linda Ford, David Pearlman, Sheldon Spector, Lawrence Sher, Franck Skobieranda, Lin Wang, Stephane Kirkesseli, Ross Rocklin, Brian Bock,[...]. N Engl J Med 2013
842
14

Tezepelumab in Adults with Uncontrolled Asthma.
Jonathan Corren, Jane R Parnes, Liangwei Wang, May Mo, Stephanie L Roseti, Janet M Griffiths, René van der Merwe. N Engl J Med 2017
441
14

Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Claus Bachert, Joseph K Han, Martin Desrosiers, Peter W Hellings, Nikhil Amin, Stella E Lee, Joaquim Mullol, Leon S Greos, John V Bosso, Tanya M Laidlaw,[...]. Lancet 2019
391
14

Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials.
Philippe Gevaert, Theodore A Omachi, Jonathan Corren, Joaquim Mullol, Joseph Han, Stella E Lee, Derrick Kaufman, Monica Ligueros-Saylan, Monet Howard, Rui Zhu,[...]. J Allergy Clin Immunol 2020
170
14

Randomized trial of omalizumab (anti-IgE) for asthma in inner-city children.
William W Busse, Wayne J Morgan, Peter J Gergen, Herman E Mitchell, James E Gern, Andrew H Liu, Rebecca S Gruchalla, Meyer Kattan, Stephen J Teach, Jacqueline A Pongracic,[...]. N Engl J Med 2011
582
14

Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study.
Mario Castro, Sameer Mathur, Frederick Hargreave, Louis-Philippe Boulet, Fang Xie, James Young, H Jeffrey Wilkins, Timothy Henkel, Parameswaran Nair. Am J Respir Crit Care Med 2011
470
13



Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study.
Marc Humbert, Camille Taillé, Laurence Mala, Vincent Le Gros, Jocelyne Just, Mathieu Molimard. Eur Respir J 2018
109
12

Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial.
William W Busse, Eugene R Bleecker, J Mark FitzGerald, Gary T Ferguson, Peter Barker, Stephanie Sproule, Richard F Olsson, Ubaldo J Martin, Mitchell Goldman. Lancet Respir Med 2019
121
12

Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study.
Thomas B Casale, Allan T Luskin, William Busse, Robert S Zeiger, Benjamin Trzaskoma, Ming Yang, Noelle M Griffin, Bradley E Chipps. J Allergy Clin Immunol Pract 2019
90
13

Long-term Efficacy and Safety of Mepolizumab in Patients With Severe Eosinophilic Asthma: A Multi-center, Open-label, Phase IIIb Study.
Njira Lugogo, Christian Domingo, Pascal Chanez, Richard Leigh, Martyn J Gilson, Robert G Price, Steven W Yancey, Hector G Ortega. Clin Ther 2016
141
11

Weight-adjusted Intravenous Reslizumab in Severe Asthma with Inadequate Response to Fixed-Dose Subcutaneous Mepolizumab.
Manali Mukherjee, Fernando Aleman Paramo, Melanie Kjarsgaard, Brittany Salter, Gayatri Nair, Nicola LaVigne, Katherine Radford, Roma Sehmi, Parameswaran Nair. Am J Respir Crit Care Med 2018
103
11

Omalizumab for the treatment of chronic idiopathic or spontaneous urticaria.
Marcus Maurer, Karin Rosén, Hsin-Ju Hsieh, Sarbjit Saini, Clive Grattan, Ana Gimenéz-Arnau, Sunil Agarwal, Ramona Doyle, Janice Canvin, Allen Kaplan,[...]. N Engl J Med 2013
577
11

Mepolizumab for prednisone-dependent asthma with sputum eosinophilia.
Parameswaran Nair, Marcia M M Pizzichini, Melanie Kjarsgaard, Mark D Inman, Ann Efthimiadis, Emilio Pizzichini, Frederick E Hargreave, Paul M O'Byrne. N Engl J Med 2009
961
10

Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
H Milgrom, W Berger, A Nayak, N Gupta, S Pollard, M McAlary, A F Taylor, P Rohane. Pediatrics 2001
318
10

Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Hector G Ortega, Steven W Yancey, Bhabita Mayer, Necdet B Gunsoy, Oliver N Keene, Eugene R Bleecker, Christopher E Brightling, Ian D Pavord. Lancet Respir Med 2016
295
10

Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
Sumita Khatri, Wendy Moore, Peter G Gibson, Richard Leigh, Arnaud Bourdin, Jorge Maspero, Manuel Barros, Roland Buhl, Peter Howarth, Frank C Albers,[...]. J Allergy Clin Immunol 2019
112
10

Persistency of response to omalizumab therapy in severe allergic (IgE-mediated) asthma.
J Bousquet, Z Siergiejko, E Swiebocka, M Humbert, K F Rabe, N Smith, J Leo, C Peckitt, R Maykut, G Peachey. Allergy 2011
113
10

Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma.
Joanne E Kavanagh, Andrew P Hearn, Jaideep Dhariwal, Gráinne d'Ancona, Abdel Douiri, Cris Roxas, Mariana Fernandes, Linda Green, Louise Thomson, Alexandra M Nanzer,[...]. Chest 2021
64
15

Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma.
Andrew Menzies-Gow, Jonathan Corren, Arnaud Bourdin, Geoffrey Chupp, Elliot Israel, Michael E Wechsler, Christopher E Brightling, Janet M Griffiths, Åsa Hellqvist, Karin Bowen,[...]. N Engl J Med 2021
98
10

Lebrikizumab treatment in adults with asthma.
Jonathan Corren, Robert F Lemanske, Nicola A Hanania, Phillip E Korenblat, Merdad V Parsey, Joseph R Arron, Jeffrey M Harris, Heleen Scheerens, Lawren C Wu, Zheng Su,[...]. N Engl J Med 2011
9

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
Bob Lanier, Tracy Bridges, Marek Kulus, Angel Fowler Taylor, Indrias Berhane, Carlos Fernandez Vidaurre. J Allergy Clin Immunol 2009
213
9

Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations.
Stephen J Teach, Michelle A Gill, Alkis Togias, Christine A Sorkness, Samuel J Arbes, Agustin Calatroni, Jeremy J Wildfire, Peter J Gergen, Robyn T Cohen, Jacqueline A Pongracic,[...]. J Allergy Clin Immunol 2015
315
9

"Real-life" Effectiveness Studies of Omalizumab in Adult Patients with Severe Allergic Asthma: Meta-analysis.
Abdulaziz Alhossan, Christopher S Lee, Karen MacDonald, Ivo Abraham. J Allergy Clin Immunol Pract 2017
57
15

Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma.
T B Casale, B E Chipps, K Rosén, B Trzaskoma, T Haselkorn, T A Omachi, S Greenberg, N A Hanania. Allergy 2018
80
11

Benralizumab, an anti-interleukin 5 receptor α monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study.
Mario Castro, Sally E Wenzel, Eugene R Bleecker, Emilio Pizzichini, Piotr Kuna, William W Busse, David L Gossage, Christine K Ward, Yanping Wu, Bing Wang,[...]. Lancet Respir Med 2014
332
9

A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma.
Patrick Flood-Page, Cheri Swenson, Isidore Faiferman, John Matthews, Michael Williams, Lesley Brannick, Douglas Robinson, Sally Wenzel, William Busse, Trevor T Hansel,[...]. Am J Respir Crit Care Med 2007
511
9


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.